Minervax
Per Fischer is the current CEO at Minervax and has previously held various positions at different companies such as Helion Biotech ApS, FGP Import, Fischer BioConsult ApS, NatImmune A/S, Bavarian Nordic A/S, Novo Nordisk A/S, and Novo Nordisk Pharmaceuticals. Per has a wealth of experience in the biotech industry and has been instrumental in the development and success of various projects and initiatives.
Per Fischer began their educational career by obtaining a M.Sc. in Experimental Cellular Biology from Syddansk Universitet - University of Southern Denmark. Per then went on to obtain a D.Phil. in Biochemistry from the University of Oxford.
Some individuals on their team include Bjørn Kantsø - CTO, Head of CMC, Bengt Johansson Lindbom - CSO, and Bo Danner Henriksen - CFO.
Minervax
Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.